

Global Pulmonary Drug Delivery and Inhalation Devices Market Growth 2026-2032

<https://marketpublishers.com/r/GF447EBBE122EN.html>

Date: October 2026

Pages: 153

Price: US\$ 3,660.00 (Single User License)

ID: GF447EBBE122EN

Abstracts

The global Pulmonary Drug Delivery and Inhalation Devices market size is predicted to grow from US\$ 16214 million in 2025 to US\$ 21896 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.

Pulmonary Drug Delivery and Inhalation Devices refer to medical drug-delivery systems designed to generate, meter, aerosolize, disperse, and deliver pharmaceutical formulations through the respiratory tract, primarily for deposition in the lungs and airways. The market covered in this study centers on Pressurized Metered-dose Inhalers, Dry Powder Inhalers, Nebulizers, and Soft Mist Inhalers, together with conventional mechanical and smart connected device configurations used in pulmonary therapy. Device performance depends on the interaction among formulation properties, aerosol generation mechanism, particle or droplet characteristics, metering accuracy, airflow resistance, patient inspiratory capability, and human-factor design. The FDA recognizes metered-dose and dry-powder inhalers as products that deliver drug substances through the inhalation route, while nebulization systems convert liquid formulations into respirable aerosols using pneumatic, ultrasonic, vibrating-mesh or related technologies. This study focuses on devices used across Homecare, Hospital & Clinic and other professional care settings, with major therapeutic applications in Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and other pulmonary disorders requiring localized or systemic inhaled drug delivery.

Key Findings

Pulmonary Drug Delivery and Inhalation Devices are structured around pMDIs, DPIs, Nebulizers and Soft Mist Inhalers

Asthma and COPD remain the principal application foundations, while CF and other pulmonary diseases support specialized inhalation demand

Smart Connected Inhalation Devices are shifting product differentiation toward adherence monitoring, dose tracking and inhalation-technique feedback

Low-GWP pMDI technology and portable vibrating-mesh nebulization are becoming important technology-upgrade directions

Market Trends

The Pulmonary Drug Delivery and Inhalation Devices industry is moving from basic aerosol generation toward patient-centric, environmentally sustainable and digitally supported drug delivery. Device selection is increasingly linked not only to the pharmaceutical formulation but also to the patient's inspiratory flow, hand-breath coordination, dexterity, age, cognitive capability and ability to use the device correctly. GINA emphasizes that inhaler selection should consider whether patients can correctly operate the device after training and notes that incorrect technique and poor adherence can materially affect asthma outcomes; electronic inhaler monitoring is also increasingly used to identify adherence problems. At the technology level, vibrating-mesh nebulizers are improving portability, treatment speed, quietness and aerosol control, while connected inhalers are adding usage sensing, dose monitoring, technique assessment and healthcare-data functions. Sustainability is becoming another structural innovation driver. The EU has incorporated metered-dose inhalers into its HFC quota framework, while the EMA has established requirements for transitioning pMDIs toward low-global-warming-potential propellants. GSK and AstraZeneca are among companies progressing lower-carbon or next-generation-propellant pMDI programs, indicating that environmental redesign is becoming part of inhaler lifecycle management rather than a peripheral product feature.

Market Dynamics

Drivers

Demand for Pulmonary Drug Delivery and Inhalation Devices is fundamentally supported by the long-term treatment requirements of asthma, COPD and other chronic respiratory diseases, where repeated inhaled administration creates recurring demand for reliable and patient-compatible drug-delivery platforms. Inhaled therapy can deliver

medication directly to the respiratory tract, while device choice allows treatment to be adapted to patient capability and clinical setting. pMDIs and DPIs provide highly portable maintenance and rescue-treatment formats, whereas nebulizers can reduce the requirement for complex hand-breath coordination and therefore remain important for pediatric, elderly, debilitated and acute-care patients. Continued development of single-inhaler combination therapies, portable nebulization systems and home-based chronic disease management is further increasing the strategic importance of device usability, dose consistency and treatment convenience.

Restraints

The market is constrained by the close interdependence between drug formulation and device performance. Different inhaler types require different breathing techniques, and DPIs depend substantially on adequate inspiratory flow, while conventional pMDIs can require precise coordination between actuation and inhalation. Nebulizers simplify some aspects of administration but may introduce treatment-time, cleaning, maintenance and power-supply requirements. Development barriers are also higher than for conventional stand-alone medical devices because many inhaler products function as drug-device combination products and require extensive control of aerosol performance, metering accuracy, particle-size distribution, container-closure compatibility and manufacturing consistency. For pMDI manufacturers, transition toward new low-GWP propellants additionally requires formulation, material compatibility, performance and regulatory bridging work, increasing development complexity in the near term.

Opportunities

The principal opportunity lies in upgrading Pulmonary Drug Delivery and Inhalation Devices from passive administration tools into integrated therapeutic platforms. Smart Connected Inhalation Devices can record usage events, monitor remaining doses, evaluate inhalation technique and transmit information to digital health systems, creating opportunities in adherence management and remote chronic-disease monitoring. Advanced nebulization represents another opportunity, particularly vibrating-mesh and breath-triggered systems capable of improving portability, reducing treatment burden and supporting drug-specific aerosol delivery. PARI and other inhalation technology developers are increasingly working with pharmaceutical partners on customized nebulizer platforms, while Phillips Medisize has expanded its inhalation capabilities into small molecules, biologics, complex formulations, pMDIs, DPIs and nebulization following the integration of Vectura capabilities. This broadens the addressable opportunity from conventional respiratory medicines toward higher-value inhaled therapies requiring optimized formulation-device combinations.

Challenges

The long-term challenge is to simultaneously improve clinical performance, usability, sustainability and manufacturing economics without introducing additional patient complexity. Inhaler platforms must deliver reproducible doses under variable real-world inhalation conditions, while connected devices must add useful digital functionality without compromising reliability or creating excessive software, data-management and user-interface burdens. The coexistence of pMDIs, DPIs, Soft Mist Inhalers and multiple nebulizer technologies also means that patient training remains structurally important because operating techniques are not interchangeable. Manufacturers must also manage the transition to environmentally improved propellants while retaining equivalent aerosol and therapeutic performance, an issue that requires substantial formulation and device re-engineering. As competition shifts toward integrated drug-device solutions, the ability to combine pharmaceutical science, aerosol engineering, human factors, regulatory capabilities and scalable manufacturing becomes increasingly critical.

Industry Chain Analysis

The Pulmonary Drug Delivery and Inhalation Devices industry chain begins with pharmaceutical active ingredients and inhalation formulations, alongside device materials and components such as engineering plastics, metal canisters, elastomers, metering valves, actuators, powder reservoirs, capsules or blisters, compressors, vibrating-mesh elements, electronics, sensors and connectivity modules. In the midstream, inhalation-device developers integrate formulation characteristics with aerosol-generation and metering technologies to create pMDIs, DPIs, Nebulizers and Soft Mist Inhalers, followed by pharmaceutical filling, assembly, performance testing, combination-product validation and scaled manufacturing. FDA guidance highlights the importance of delivered particle-size distribution and aerosol performance, illustrating why formulation, container-closure system and delivery-device engineering must be developed as an integrated system. Downstream demand comes from pharmaceutical companies, hospitals and clinics, pharmacies, distributors and Homecare users. Value creation is therefore concentrated not simply in device manufacturing, but in reliable pulmonary deposition, accurate and repeatable dosing, drug-device compatibility, patient usability, regulatory evidence and manufacturability at commercial scale. Specialized suppliers such as Aptar Pharma and Phillips Medisize increasingly participate across multiple stages, from metering and device platforms through formulation support, development and manufacturing, reflecting a shift toward more integrated inhalation-development ecosystems.

Segment Insights

By Type, Pressurized Metered-dose Inhalers and Dry Powder Inhalers remain the core portable inhaler architectures for chronic respiratory treatment. pMDIs provide compact multidose delivery but require close control of formulation, propellant, valve, canister and actuator performance; the segment is now entering a significant technology transition toward low-GWP propellants. DPIs avoid propellants and can offer breath-actuated delivery, but their performance is more dependent on patient inspiratory flow and powder formulation characteristics. Soft Mist Inhalers occupy a differentiated position by mechanically generating a slow-moving aerosol mist, while Nebulizers remain particularly important where normal tidal breathing, liquid formulations or reduced coordination requirements are preferred.

Within Nebulizers, the technology mix is moving beyond conventional compressor-driven jet systems toward compact mesh-based platforms. OMRON distinguishes compressor nebulizers, which use compressed air, from mesh systems that use high-frequency vibration to force medication through fine apertures; Aerogen similarly uses vibrating-mesh technology to generate respirable droplets for acute-care and other pulmonary drug-delivery settings. By Intelligence, Conventional Inhalation Devices remain the installed base, while Smart Connected Inhalation Devices represent a higher-value development direction through dose counting, event recording, adherence assessment and technique feedback. Device intelligence is therefore becoming an additional segmentation dimension layered onto the traditional pMDI, DPI, nebulizer and soft-mist technology structure.

Downstream Market Opportunities

Asthma and Chronic Obstructive Pulmonary Disease (COPD) form the broadest recurring-use foundation for Pulmonary Drug Delivery and Inhalation Devices because both diseases rely extensively on inhaled maintenance and/or reliever therapies, and clinical guidelines emphasize correct inhaler selection, technique and adherence as integral components of treatment. Cystic Fibrosis (CF) represents an important specialized market for nebulized therapies, where aerosolized antibiotics and other inhaled treatments require efficient lung deposition and drug-specific delivery systems; PARI identifies CF as a major application area for its nebulization platforms. IPF and broader fibrotic or rare pulmonary diseases offer emerging opportunities as pharmaceutical developers investigate inhaled formulations intended to increase local pulmonary exposure while potentially reducing systemic exposure. PARI's current pharmaceutical-partner activities include development programs involving inhaled

therapies for progressive pulmonary fibrosis, illustrating the extension of advanced inhalation technology beyond traditional obstructive respiratory diseases. From an End-user perspective, Homecare benefits from compact, battery-powered, quiet and easy-to-use platforms, while Hospital & Clinic demand emphasizes reliable aerosol delivery across acute, ventilated and non-ventilated respiratory care.

Regional Insights

North America and Europe are high-value mature markets for Pulmonary Drug Delivery and Inhalation Devices, characterized by broad use of combination inhaled therapies, established regulatory frameworks for drug-device combination products and active adoption of next-generation inhaler technologies. Europe is also becoming an important regulatory catalyst for sustainable pMDI redesign because the EU fluorinated-gas framework and EMA guidance are accelerating the transition toward lower-GWP propellants. North America remains important for advanced pharmaceutical inhaler launches, connected drug-delivery solutions and specialized respiratory devices, supported by a developed pharmaceutical and respiratory-care ecosystem. Asia-Pacific provides substantial expansion potential across both pharmaceutical inhalers and Homecare nebulization as access to chronic respiratory treatment increases and regional manufacturers expand portable compressor and mesh-nebulizer offerings. Competitive positioning therefore differs by region: developed markets place greater weight on combination therapy, digital adherence, sustainability and lifecycle management, while emerging markets continue to combine technology upgrading with affordability, distribution coverage and broader access to respiratory treatment.

Competitive Landscape Analysis

Competition in Pulmonary Drug Delivery and Inhalation Devices is multi-layered because the market combines pharmaceutical drug-device franchises, specialist inhalation-platform suppliers and respiratory medical-device manufacturers. GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Novartis and other pharmaceutical companies compete primarily through proprietary inhaled medicines and integrated inhaler platforms; GSK's current respiratory portfolio includes Ellipta-based products and Ventolin, while AstraZeneca markets both pMDI and DPI respiratory products and is expanding single-inhaler combination therapy. Aptar Pharma competes further upstream through pMDI metering valves, DPIs, breath-actuated inhalers and connected-device technologies, while Phillips Medisize has strengthened its position in formulation, inhaler design and combination-product development following the 2025 integration of Vectura capabilities. In nebulization, PARI, Aerogen, OMRON, Yuwell and other

respiratory-device manufacturers compete around aerosol efficiency, portability, treatment time, noise, usability and application-specific device design. The competitive focus is consequently shifting away from stand-alone hardware specifications toward integrated drug-device performance, patient experience, sustainability, digital functions, intellectual property and the ability to support pharmaceutical partners through development and commercialization.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “Pulmonary Drug Delivery and Inhalation Devices Industry Forecast” looks at past sales and reviews total world Pulmonary Drug Delivery and Inhalation Devices sales in 2025, providing a comprehensive analysis by region and market sector of projected Pulmonary Drug Delivery and Inhalation Devices sales for 2026 through 2032. With Pulmonary Drug Delivery and Inhalation Devices sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Pulmonary Drug Delivery and Inhalation Devices industry.

This Insight Report provides a comprehensive analysis of the global Pulmonary Drug Delivery and Inhalation Devices landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Drug Delivery and Inhalation Devices portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pulmonary Drug Delivery and Inhalation Devices market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Drug Delivery and Inhalation Devices and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Drug Delivery and Inhalation Devices.

This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Drug Delivery and Inhalation Devices market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Type:

Pressurized Metered-dose Inhalers

Dry Powder Inhalers

Nebulizers

Soft Mist Inhalers

Segmentation by Intelligence:

Conventional Inhalation Devices

Smart Connected Inhalation Devices

Segmentation by End-Users:

Homecare

Hospital & Clinic

Others

Segmentation by Application:

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Cystic Fibrosis (CF)

Idiopathic Pulmonary Fibrosis (IPF)

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

GSK

AstraZeneca

Aptar Pharma

Chiesi

Boehringer Ingelheim

Novartis

OMRON

Philips

Organon

PARI GmbH

Aerogen

Teva Pharmaceuticals

Phillips Medisize (Molex)

Drive DeVilbiss Healthcare

Monaghan Medical

Yuwell

BMC Medical

Folee

Beurer

Entie Medical

CONTEC

Feellife

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pulmonary Drug Delivery and Inhalation Devices market?

What factors are driving Pulmonary Drug Delivery and Inhalation Devices market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pulmonary Drug Delivery and Inhalation Devices market opportunities vary by end market size?

How does Pulmonary Drug Delivery and Inhalation Devices break out by Type,
by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Pulmonary Drug Delivery and Inhalation Devices Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Pulmonary Drug Delivery and Inhalation Devices by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Pulmonary Drug Delivery and Inhalation Devices by Country/Region, 2021, 2025 & 2032

2.2 Pulmonary Drug Delivery and Inhalation Devices Segment by Type

- 2.2.1 Pressurized Metered-dose Inhalers
- 2.2.2 Dry Powder Inhalers
- 2.2.3 Nebulizers
- 2.2.4 Soft Mist Inhalers
- 2.2.5 Pulmonary Drug Delivery and Inhalation Devices Sales by Type
 - 2.2.5.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Type (2021-2026)
 - 2.2.5.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue and Market Share by Type (2021-2026)
 - 2.2.5.3 Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by Type (2021-2026)

2.3 Pulmonary Drug Delivery and Inhalation Devices Segment by Intelligence

- 2.3.1 Conventional Inhalation Devices
- 2.3.2 Smart Connected Inhalation Devices
- 2.3.3 Pulmonary Drug Delivery and Inhalation Devices Sales by Intelligence
 - 2.3.3.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Intelligence (2021-2026)

2.3.3.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue and Market Share by Intelligence (2021-2026)

2.3.3.3 Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by Intelligence (2021-2026)

2.4 Pulmonary Drug Delivery and Inhalation Devices Segment by End-Users

2.4.1 Homecare

2.4.2 Hospital & Clinic

2.4.3 Others

2.4.4 Pulmonary Drug Delivery and Inhalation Devices Sales by End-Users

2.4.4.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by End-Users (2021-2026)

2.4.4.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue and Market Share by End-Users (2021-2026)

2.4.4.3 Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by End-Users (2021-2026)

2.5 Pulmonary Drug Delivery and Inhalation Devices Segment by Application

2.5.1 Asthma

2.5.2 Chronic Obstructive Pulmonary Disease (COPD)

2.5.3 Cystic Fibrosis (CF)

2.5.4 Idiopathic Pulmonary Fibrosis (IPF)

2.5.5 Others

2.5.6 Pulmonary Drug Delivery and Inhalation Devices Sales by Application

2.5.6.1 Global Pulmonary Drug Delivery and Inhalation Devices Sale Market Share by Application (2021-2026)

2.5.6.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue and Market Share by Application (2021-2026)

2.5.6.3 Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Pulmonary Drug Delivery and Inhalation Devices Breakdown Data by Company

3.1.1 Global Pulmonary Drug Delivery and Inhalation Devices Annual Sales by Company (2021-2026)

3.1.2 Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Company (2021-2026)

3.2 Global Pulmonary Drug Delivery and Inhalation Devices Annual Revenue by Company (2021-2026)

3.2.1 Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Company (2021-2026)

3.2.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Company (2021-2026)

3.3 Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by Company

3.4 Key Manufacturers Pulmonary Drug Delivery and Inhalation Devices Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Pulmonary Drug Delivery and Inhalation Devices Product Location Distribution

3.4.2 Players Pulmonary Drug Delivery and Inhalation Devices Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PULMONARY DRUG DELIVERY AND INHALATION DEVICES BY GEOGRAPHIC REGION

4.1 World Historic Pulmonary Drug Delivery and Inhalation Devices Market Size by Geographic Region (2021-2026)

4.1.1 Global Pulmonary Drug Delivery and Inhalation Devices Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Pulmonary Drug Delivery and Inhalation Devices Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Pulmonary Drug Delivery and Inhalation Devices Market Size by Country/Region (2021-2026)

4.2.1 Global Pulmonary Drug Delivery and Inhalation Devices Annual Sales by Country/Region (2021-2026)

4.2.2 Global Pulmonary Drug Delivery and Inhalation Devices Annual Revenue by Country/Region (2021-2026)

4.3 Americas Pulmonary Drug Delivery and Inhalation Devices Sales Growth

4.4 APAC Pulmonary Drug Delivery and Inhalation Devices Sales Growth

4.5 Europe Pulmonary Drug Delivery and Inhalation Devices Sales Growth

4.6 Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales Growth

5 AMERICAS

5.1 Americas Pulmonary Drug Delivery and Inhalation Devices Sales by Country

5.1.1 Americas Pulmonary Drug Delivery and Inhalation Devices Sales by Country
(2021-2026)

5.1.2 Americas Pulmonary Drug Delivery and Inhalation Devices Revenue by Country
(2021-2026)

5.2 Americas Pulmonary Drug Delivery and Inhalation Devices Sales by Type
(2021-2026)

5.3 Americas Pulmonary Drug Delivery and Inhalation Devices Sales by Application
(2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Pulmonary Drug Delivery and Inhalation Devices Sales by Region

6.1.1 APAC Pulmonary Drug Delivery and Inhalation Devices Sales by Region
(2021-2026)

6.1.2 APAC Pulmonary Drug Delivery and Inhalation Devices Revenue by Region
(2021-2026)

6.2 APAC Pulmonary Drug Delivery and Inhalation Devices Sales by Type (2021-2026)

6.3 APAC Pulmonary Drug Delivery and Inhalation Devices Sales by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Pulmonary Drug Delivery and Inhalation Devices by Country

7.1.1 Europe Pulmonary Drug Delivery and Inhalation Devices Sales by Country
(2021-2026)

7.1.2 Europe Pulmonary Drug Delivery and Inhalation Devices Revenue by Country
(2021-2026)

7.2 Europe Pulmonary Drug Delivery and Inhalation Devices Sales by Type

(2021-2026)

7.3 Europe Pulmonary Drug Delivery and Inhalation Devices Sales by Application

(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices by Country

8.1.1 Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales by Country (2021-2026)

8.1.2 Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Revenue by Country (2021-2026)

8.2 Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales by Type (2021-2026)

8.3 Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Pulmonary Drug Delivery and Inhalation Devices

10.3 Manufacturing Process Analysis of Pulmonary Drug Delivery and Inhalation Devices

10.4 Industry Chain Structure of Pulmonary Drug Delivery and Inhalation Devices

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Pulmonary Drug Delivery and Inhalation Devices Distributors

11.3 Pulmonary Drug Delivery and Inhalation Devices Customer

12 WORLD FORECAST REVIEW FOR PULMONARY DRUG DELIVERY AND INHALATION DEVICES BY GEOGRAPHIC REGION

12.1 Global Pulmonary Drug Delivery and Inhalation Devices Market Size Forecast by Region

12.1.1 Global Pulmonary Drug Delivery and Inhalation Devices Forecast by Region (2027-2032)

12.1.2 Global Pulmonary Drug Delivery and Inhalation Devices Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Pulmonary Drug Delivery and Inhalation Devices Forecast by Type (2027-2032)

12.7 Global Pulmonary Drug Delivery and Inhalation Devices Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 GSK

13.1.1 GSK Company Information

13.1.2 GSK Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

13.1.3 GSK Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 GSK Main Business Overview

13.1.5 GSK Latest Developments

13.2 AstraZeneca

- 13.2.1 AstraZeneca Company Information
- 13.2.2 AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
- 13.2.3 AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.2.4 AstraZeneca Main Business Overview
- 13.2.5 AstraZeneca Latest Developments
- 13.3 Aptar Pharma
- 13.3.1 Aptar Pharma Company Information
- 13.3.2 Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
- 13.3.3 Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.3.4 Aptar Pharma Main Business Overview
- 13.3.5 Aptar Pharma Latest Developments
- 13.4 Chiesi
- 13.4.1 Chiesi Company Information
- 13.4.2 Chiesi Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
- 13.4.3 Chiesi Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.4.4 Chiesi Main Business Overview
- 13.4.5 Chiesi Latest Developments
- 13.5 Boehringer Ingelheim
- 13.5.1 Boehringer Ingelheim Company Information
- 13.5.2 Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
- 13.5.3 Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.5.4 Boehringer Ingelheim Main Business Overview
- 13.5.5 Boehringer Ingelheim Latest Developments
- 13.6 Novartis
- 13.6.1 Novartis Company Information
- 13.6.2 Novartis Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
- 13.6.3 Novartis Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.6.4 Novartis Main Business Overview
- 13.6.5 Novartis Latest Developments

13.7 OMRON

13.7.1 OMRON Company Information

13.7.2 OMRON Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

13.7.3 OMRON Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 OMRON Main Business Overview

13.7.5 OMRON Latest Developments

13.8 Philips

13.8.1 Philips Company Information

13.8.2 Philips Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

13.8.3 Philips Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Philips Main Business Overview

13.8.5 Philips Latest Developments

13.9 Organon

13.9.1 Organon Company Information

13.9.2 Organon Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

13.9.3 Organon Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Organon Main Business Overview

13.9.5 Organon Latest Developments

13.10 PARI GmbH

13.10.1 PARI GmbH Company Information

13.10.2 PARI GmbH Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

13.10.3 PARI GmbH Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 PARI GmbH Main Business Overview

13.10.5 PARI GmbH Latest Developments

13.11 Aerogen

13.11.1 Aerogen Company Information

13.11.2 Aerogen Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

13.11.3 Aerogen Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Aerogen Main Business Overview

- 13.11.5 Aerogen Latest Developments
- 13.12 Teva Pharmaceuticals
 - 13.12.1 Teva Pharmaceuticals Company Information
 - 13.12.2 Teva Pharmaceuticals Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.12.3 Teva Pharmaceuticals Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.12.4 Teva Pharmaceuticals Main Business Overview
 - 13.12.5 Teva Pharmaceuticals Latest Developments
- 13.13 Phillips Medisize (Molex)
 - 13.13.1 Phillips Medisize (Molex) Company Information
 - 13.13.2 Phillips Medisize (Molex) Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.13.3 Phillips Medisize (Molex) Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.13.4 Phillips Medisize (Molex) Main Business Overview
 - 13.13.5 Phillips Medisize (Molex) Latest Developments
- 13.14 Drive DeVilbiss Healthcare
 - 13.14.1 Drive DeVilbiss Healthcare Company Information
 - 13.14.2 Drive DeVilbiss Healthcare Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.14.3 Drive DeVilbiss Healthcare Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.14.4 Drive DeVilbiss Healthcare Main Business Overview
 - 13.14.5 Drive DeVilbiss Healthcare Latest Developments
- 13.15 Monaghan Medical
 - 13.15.1 Monaghan Medical Company Information
 - 13.15.2 Monaghan Medical Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.15.3 Monaghan Medical Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.15.4 Monaghan Medical Main Business Overview
 - 13.15.5 Monaghan Medical Latest Developments
- 13.16 Yuwell
 - 13.16.1 Yuwell Company Information
 - 13.16.2 Yuwell Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.16.3 Yuwell Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.16.4 Yuwell Main Business Overview
- 13.16.5 Yuwell Latest Developments
- 13.17 BMC Medical
 - 13.17.1 BMC Medical Company Information
 - 13.17.2 BMC Medical Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.17.3 BMC Medical Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.17.4 BMC Medical Main Business Overview
 - 13.17.5 BMC Medical Latest Developments
- 13.18 Folee
 - 13.18.1 Folee Company Information
 - 13.18.2 Folee Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.18.3 Folee Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.18.4 Folee Main Business Overview
 - 13.18.5 Folee Latest Developments
- 13.19 Beurer
 - 13.19.1 Beurer Company Information
 - 13.19.2 Beurer Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.19.3 Beurer Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.19.4 Beurer Main Business Overview
 - 13.19.5 Beurer Latest Developments
- 13.20 Entie Medical
 - 13.20.1 Entie Medical Company Information
 - 13.20.2 Entie Medical Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.20.3 Entie Medical Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.20.4 Entie Medical Main Business Overview
 - 13.20.5 Entie Medical Latest Developments
- 13.21 CONTEC
 - 13.21.1 CONTEC Company Information
 - 13.21.2 CONTEC Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
 - 13.21.3 CONTEC Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue,

Price and Gross Margin (2021-2026)

13.21.4 CONTEC Main Business Overview

13.21.5 CONTEC Latest Developments

13.22 Feellife

13.22.1 Feellife Company Information

13.22.2 Feellife Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

13.22.3 Feellife Pulmonary Drug Delivery and Inhalation Devices Sales, Revenue, Price and Gross Margin (2021-2026)

13.22.4 Feellife Main Business Overview

13.22.5 Feellife Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Pulmonary Drug Delivery and Inhalation Devices Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Pulmonary Drug Delivery and Inhalation Devices Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Pressurized Metered-dose Inhalers

Table 4. Major Players of Dry Powder Inhalers

Table 5. Major Players of Nebulizers

Table 6. Major Players of Soft Mist Inhalers

Table 7. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Type (2021-2026) & (K Units)

Table 8. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Type (2021-2026)

Table 9. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Type (2021-2026) & (\$ million)

Table 10. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Type (2021-2026)

Table 11. Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by Type (2021-2026) & (K US\$/Unit)

Table 12. Major Players of Conventional Inhalation Devices

Table 13. Major Players of Smart Connected Inhalation Devices

Table 14. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Intelligence (2021-2026) & (K Units)

Table 15. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Intelligence (2021-2026)

Table 16. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Intelligence (2021-2026) & (\$ million)

Table 17. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Intelligence (2021-2026)

Table 18. Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by Intelligence (2021-2026) & (K US\$/Unit)

Table 19. Major Players of Homecare

Table 20. Major Players of Hospital & Clinic

Table 21. Major Players of Others

Table 22. Global Pulmonary Drug Delivery and Inhalation Devices Sales by End-Users (2021-2026) & (K Units)

Table 23. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by End-Users (2021-2026)

Table 24. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by End-Users (2021-2026) & (\$ million)

Table 25. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by End-Users (2021-2026)

Table 26. Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by End-Users (2021-2026) & (K US\$/Unit)

Table 27. Global Pulmonary Drug Delivery and Inhalation Devices Sale by Application (2021-2026) & (K Units)

Table 28. Global Pulmonary Drug Delivery and Inhalation Devices Sale Market Share by Application (2021-2026)

Table 29. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Application (2021-2026) & (\$ million)

Table 30. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Application (2021-2026)

Table 31. Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by Application (2021-2026) & (K US\$/Unit)

Table 32. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Company (2021-2026) & (K Units)

Table 33. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Company (2021-2026)

Table 34. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Company (2021-2026) & (\$ millions)

Table 35. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Company (2021-2026)

Table 36. Global Pulmonary Drug Delivery and Inhalation Devices Sale Price by Company (2021-2026) & (K US\$/Unit)

Table 37. Key Manufacturers Pulmonary Drug Delivery and Inhalation Devices Producing Area Distribution and Sales Area

Table 38. Players Pulmonary Drug Delivery and Inhalation Devices Products Offered

Table 39. Pulmonary Drug Delivery and Inhalation Devices Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 40. New Products and Potential Entrants

Table 41. Market M&A Activity & Strategy

Table 42. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Geographic Region (2021-2026) & (K Units)

Table 43. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share Geographic Region (2021-2026)

Table 44. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 45. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Geographic Region (2021-2026)

Table 46. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Country/Region (2021-2026) & (K Units)

Table 47. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Country/Region (2021-2026)

Table 48. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Country/Region (2021-2026) & (\$ millions)

Table 49. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Country/Region (2021-2026)

Table 50. Americas Pulmonary Drug Delivery and Inhalation Devices Sales by Country (2021-2026) & (K Units)

Table 51. Americas Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Country (2021-2026)

Table 52. Americas Pulmonary Drug Delivery and Inhalation Devices Revenue by Country (2021-2026) & (\$ millions)

Table 53. Americas Pulmonary Drug Delivery and Inhalation Devices Sales by Type (2021-2026) & (K Units)

Table 54. Americas Pulmonary Drug Delivery and Inhalation Devices Sales by Application (2021-2026) & (K Units)

Table 55. APAC Pulmonary Drug Delivery and Inhalation Devices Sales by Region (2021-2026) & (K Units)

Table 56. APAC Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Region (2021-2026)

Table 57. APAC Pulmonary Drug Delivery and Inhalation Devices Revenue by Region (2021-2026) & (\$ millions)

Table 58. APAC Pulmonary Drug Delivery and Inhalation Devices Sales by Type (2021-2026) & (K Units)

Table 59. APAC Pulmonary Drug Delivery and Inhalation Devices Sales by Application (2021-2026) & (K Units)

Table 60. Europe Pulmonary Drug Delivery and Inhalation Devices Sales by Country (2021-2026) & (K Units)

Table 61. Europe Pulmonary Drug Delivery and Inhalation Devices Revenue by Country (2021-2026) & (\$ millions)

Table 62. Europe Pulmonary Drug Delivery and Inhalation Devices Sales by Type (2021-2026) & (K Units)

Table 63. Europe Pulmonary Drug Delivery and Inhalation Devices Sales by Application

(2021-2026) & (K Units)

Table 64. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales by Country (2021-2026) & (K Units)

Table 65. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Country (2021-2026)

Table 66. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales by Type (2021-2026) & (K Units)

Table 67. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales by Application (2021-2026) & (K Units)

Table 68. Key Market Drivers & Growth Opportunities of Pulmonary Drug Delivery and Inhalation Devices

Table 69. Key Market Challenges & Risks of Pulmonary Drug Delivery and Inhalation Devices

Table 70. Key Industry Trends of Pulmonary Drug Delivery and Inhalation Devices

Table 71. Pulmonary Drug Delivery and Inhalation Devices Raw Material

Table 72. Key Suppliers of Raw Materials

Table 73. Pulmonary Drug Delivery and Inhalation Devices Distributors List

Table 74. Pulmonary Drug Delivery and Inhalation Devices Customer List

Table 75. Global Pulmonary Drug Delivery and Inhalation Devices Sales Forecast by Region (2027-2032) & (K Units)

Table 76. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 77. Americas Pulmonary Drug Delivery and Inhalation Devices Sales Forecast by Country (2027-2032) & (K Units)

Table 78. Americas Pulmonary Drug Delivery and Inhalation Devices Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 79. APAC Pulmonary Drug Delivery and Inhalation Devices Sales Forecast by Region (2027-2032) & (K Units)

Table 80. APAC Pulmonary Drug Delivery and Inhalation Devices Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 81. Europe Pulmonary Drug Delivery and Inhalation Devices Sales Forecast by Country (2027-2032) & (K Units)

Table 82. Europe Pulmonary Drug Delivery and Inhalation Devices Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 83. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales Forecast by Country (2027-2032) & (K Units)

Table 84. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 85. Global Pulmonary Drug Delivery and Inhalation Devices Sales Forecast by

Type (2027-2032) & (K Units)

Table 86. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 87. Global Pulmonary Drug Delivery and Inhalation Devices Sales Forecast by Application (2027-2032) & (K Units)

Table 88. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 89. GSK Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 90. GSK Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 91. GSK Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 92. GSK Main Business

Table 93. GSK Latest Developments

Table 94. AstraZeneca Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 95. AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 96. AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 97. AstraZeneca Main Business

Table 98. AstraZeneca Latest Developments

Table 99. Aptar Pharma Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 100. Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 101. Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 102. Aptar Pharma Main Business

Table 103. Aptar Pharma Latest Developments

Table 104. Chiesi Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 105. Chiesi Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 106. Chiesi Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 107. Chiesi Main Business

Table 108. Chiesi Latest Developments

Table 109. Boehringer Ingelheim Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 110. Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 111. Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 112. Boehringer Ingelheim Main Business

Table 113. Boehringer Ingelheim Latest Developments

Table 114. Novartis Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 115. Novartis Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 116. Novartis Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 117. Novartis Main Business

Table 118. Novartis Latest Developments

Table 119. OMRON Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 120. OMRON Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 121. OMRON Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 122. OMRON Main Business

Table 123. OMRON Latest Developments

Table 124. Philips Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 125. Philips Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 126. Philips Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 127. Philips Main Business

Table 128. Philips Latest Developments

Table 129. Organon Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 130. Organon Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 131. Organon Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 132. Organon Main Business

Table 133. Organon Latest Developments
Table 134. PARI GmbH Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 135. PARI GmbH Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 136. PARI GmbH Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)
Table 137. PARI GmbH Main Business
Table 138. PARI GmbH Latest Developments
Table 139. Aerogen Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 140. Aerogen Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 141. Aerogen Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)
Table 142. Aerogen Main Business
Table 143. Aerogen Latest Developments
Table 144. Teva Pharmaceuticals Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 145. Teva Pharmaceuticals Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 146. Teva Pharmaceuticals Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)
Table 147. Teva Pharmaceuticals Main Business
Table 148. Teva Pharmaceuticals Latest Developments
Table 149. Phillips Medisize (Molex) Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 150. Phillips Medisize (Molex) Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 151. Phillips Medisize (Molex) Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)
Table 152. Phillips Medisize (Molex) Main Business
Table 153. Phillips Medisize (Molex) Latest Developments
Table 154. Drive DeVilbiss Healthcare Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 155. Drive DeVilbiss Healthcare Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 156. Drive DeVilbiss Healthcare Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 157. Drive DeVilbiss Healthcare Main Business
Table 158. Drive DeVilbiss Healthcare Latest Developments
Table 159. Monaghan Medical Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 160. Monaghan Medical Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 161. Monaghan Medical Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)
Table 162. Monaghan Medical Main Business
Table 163. Monaghan Medical Latest Developments
Table 164. Yuwell Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 165. Yuwell Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 166. Yuwell Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)
Table 167. Yuwell Main Business
Table 168. Yuwell Latest Developments
Table 169. BMC Medical Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 170. BMC Medical Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 171. BMC Medical Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)
Table 172. BMC Medical Main Business
Table 173. BMC Medical Latest Developments
Table 174. Folee Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 175. Folee Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 176. Folee Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)
Table 177. Folee Main Business
Table 178. Folee Latest Developments
Table 179. Beurer Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors
Table 180. Beurer Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications
Table 181. Beurer Pulmonary Drug Delivery and Inhalation Devices Sales (K Units),

Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 182. Beurer Main Business

Table 183. Beurer Latest Developments

Table 184. Entie Medical Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 185. Entie Medical Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 186. Entie Medical Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 187. Entie Medical Main Business

Table 188. Entie Medical Latest Developments

Table 189. CONTEC Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 190. CONTEC Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 191. CONTEC Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 192. CONTEC Main Business

Table 193. CONTEC Latest Developments

Table 194. Feellife Basic Information, Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base, Sales Area and Its Competitors

Table 195. Feellife Pulmonary Drug Delivery and Inhalation Devices Product Portfolios and Specifications

Table 196. Feellife Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), Revenue (\$ Million), Price (K US\$/Unit) and Gross Margin (2021-2026)

Table 197. Feellife Main Business

Table 198. Feellife Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Pulmonary Drug Delivery and Inhalation Devices
- Figure 2. Pulmonary Drug Delivery and Inhalation Devices Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Pulmonary Drug Delivery and Inhalation Devices Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Pulmonary Drug Delivery and Inhalation Devices Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Country/Region (2025)
- Figure 10. Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Pressurized Metered-dose Inhalers
- Figure 12. Product Picture of Dry Powder Inhalers
- Figure 13. Product Picture of Nebulizers
- Figure 14. Product Picture of Soft Mist Inhalers
- Figure 15. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Type in 2026
- Figure 16. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Type (2021-2026)
- Figure 17. Product Picture of Conventional Inhalation Devices
- Figure 18. Product Picture of Smart Connected Inhalation Devices
- Figure 19. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Intelligence in 2026
- Figure 20. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Intelligence (2021-2026)
- Figure 21. Product Picture of Homecare
- Figure 22. Product Picture of Hospital & Clinic
- Figure 23. Product Picture of Others
- Figure 24. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by End-Users in 2026
- Figure 25. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market

Share by End-Users (2021-2026)

Figure 26. Pulmonary Drug Delivery and Inhalation Devices Consumed in Asthma

Figure 27. Global Pulmonary Drug Delivery and Inhalation Devices Market: Asthma (2021-2026) & (K Units)

Figure 28. Pulmonary Drug Delivery and Inhalation Devices Consumed in Chronic Obstructive Pulmonary Disease (COPD)

Figure 29. Global Pulmonary Drug Delivery and Inhalation Devices Market: Chronic Obstructive Pulmonary Disease (COPD) (2021-2026) & (K Units)

Figure 30. Pulmonary Drug Delivery and Inhalation Devices Consumed in Cystic Fibrosis (CF)

Figure 31. Global Pulmonary Drug Delivery and Inhalation Devices Market: Cystic Fibrosis (CF) (2021-2026) & (K Units)

Figure 32. Pulmonary Drug Delivery and Inhalation Devices Consumed in Idiopathic Pulmonary Fibrosis (IPF)

Figure 33. Global Pulmonary Drug Delivery and Inhalation Devices Market: Idiopathic Pulmonary Fibrosis (IPF) (2021-2026) & (K Units)

Figure 34. Pulmonary Drug Delivery and Inhalation Devices Consumed in Others

Figure 35. Global Pulmonary Drug Delivery and Inhalation Devices Market: Others (2021-2026) & (K Units)

Figure 36. Global Pulmonary Drug Delivery and Inhalation Devices Sale Market Share by Application (2025)

Figure 37. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Application in 2025

Figure 38. Pulmonary Drug Delivery and Inhalation Devices Sales by Company in 2025 (K Units)

Figure 39. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Company in 2025

Figure 40. Pulmonary Drug Delivery and Inhalation Devices Revenue by Company in 2025 (\$ millions)

Figure 41. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Company in 2025

Figure 42. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Geographic Region (2021-2026)

Figure 43. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Geographic Region in 2025

Figure 44. Americas Pulmonary Drug Delivery and Inhalation Devices Sales 2021-2026 (K Units)

Figure 45. Americas Pulmonary Drug Delivery and Inhalation Devices Revenue 2021-2026 (\$ millions)

Figure 46. APAC Pulmonary Drug Delivery and Inhalation Devices Sales 2021-2026 (K Units)

Figure 47. APAC Pulmonary Drug Delivery and Inhalation Devices Revenue 2021-2026 (\$ millions)

Figure 48. Europe Pulmonary Drug Delivery and Inhalation Devices Sales 2021-2026 (K Units)

Figure 49. Europe Pulmonary Drug Delivery and Inhalation Devices Revenue 2021-2026 (\$ millions)

Figure 50. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales 2021-2026 (K Units)

Figure 51. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Revenue 2021-2026 (\$ millions)

Figure 52. Americas Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Country in 2025

Figure 53. Americas Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Country (2021-2026)

Figure 54. Americas Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Type (2021-2026)

Figure 55. Americas Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Application (2021-2026)

Figure 56. United States Pulmonary Drug Delivery and Inhalation Devices Revenue Growth 2021-2026 (\$ millions)

Figure 57. Canada Pulmonary Drug Delivery and Inhalation Devices Revenue Growth 2021-2026 (\$ millions)

Figure 58. Mexico Pulmonary Drug Delivery and Inhalation Devices Revenue Growth 2021-2026 (\$ millions)

Figure 59. Brazil Pulmonary Drug Delivery and Inhalation Devices Revenue Growth 2021-2026 (\$ millions)

Figure 60. APAC Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Region in 2025

Figure 61. APAC Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share by Region (2021-2026)

Figure 62. APAC Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Type (2021-2026)

Figure 63. APAC Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Application (2021-2026)

Figure 64. China Pulmonary Drug Delivery and Inhalation Devices Revenue Growth 2021-2026 (\$ millions)

Figure 65. Japan Pulmonary Drug Delivery and Inhalation Devices Revenue Growth

2021-2026 (\$ millions)

Figure 66. South Korea Pulmonary Drug Delivery and Inhalation Devices Revenue

Growth 2021-2026 (\$ millions)

Figure 67. Southeast Asia Pulmonary Drug Delivery and Inhalation Devices Revenue

Growth 2021-2026 (\$ millions)

Figure 68. India Pulmonary Drug Delivery and Inhalation Devices Revenue Growth

2021-2026 (\$ millions)

Figure 69. Australia Pulmonary Drug Delivery and Inhalation Devices Revenue Growth

2021-2026 (\$ millions)

Figure 70. China Taiwan Pulmonary Drug Delivery and Inhalation Devices Revenue

Growth 2021-2026 (\$ millions)

Figure 71. Europe Pulmonary Drug Delivery and Inhalation Devices Sales Market Share
by Country in 2025

Figure 72. Europe Pulmonary Drug Delivery and Inhalation Devices Revenue Market
Share by Country (2021-2026)

Figure 73. Europe Pulmonary Drug Delivery and Inhalation Devices Sales Market Share
by Type (2021-2026)

Figure 74. Europe Pulmonary Drug Delivery and Inhalation Devices Sales Market Share
by Application (2021-2026)

Figure 75. Germany Pulmonary Drug Delivery and Inhalation Devices Revenue Growth
2021-2026 (\$ millions)

Figure 76. France Pulmonary Drug Delivery and Inhalation Devices Revenue Growth
2021-2026 (\$ millions)

Figure 77. UK Pulmonary Drug Delivery and Inhalation Devices Revenue Growth
2021-2026 (\$ millions)

Figure 78. Italy Pulmonary Drug Delivery and Inhalation Devices Revenue Growth
2021-2026 (\$ millions)

Figure 79. Russia Pulmonary Drug Delivery and Inhalation Devices Revenue Growth
2021-2026 (\$ millions)

Figure 80. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales
Market Share by Country (2021-2026)

Figure 81. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales
Market Share by Type (2021-2026)

Figure 82. Middle East & Africa Pulmonary Drug Delivery and Inhalation Devices Sales
Market Share by Application (2021-2026)

Figure 83. Egypt Pulmonary Drug Delivery and Inhalation Devices Revenue Growth
2021-2026 (\$ millions)

Figure 84. South Africa Pulmonary Drug Delivery and Inhalation Devices Revenue
Growth 2021-2026 (\$ millions)

Figure 85. Israel Pulmonary Drug Delivery and Inhalation Devices Revenue Growth 2021-2026 (\$ millions)

Figure 86. Turkey Pulmonary Drug Delivery and Inhalation Devices Revenue Growth 2021-2026 (\$ millions)

Figure 87. GCC Countries Pulmonary Drug Delivery and Inhalation Devices Revenue Growth 2021-2026 (\$ millions)

Figure 88. Manufacturing Cost Structure Analysis of Pulmonary Drug Delivery and Inhalation Devices in 2026

Figure 89. Manufacturing Process Analysis of Pulmonary Drug Delivery and Inhalation Devices

Figure 90. Industry Chain Structure of Pulmonary Drug Delivery and Inhalation Devices

Figure 91. Channels of Distribution

Figure 92. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Forecast by Region (2027-2032)

Figure 93. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share Forecast by Region (2027-2032)

Figure 94. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share Forecast by Type (2027-2032)

Figure 95. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share Forecast by Type (2027-2032)

Figure 96. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share Forecast by Application (2027-2032)

Figure 97. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Pulmonary Drug Delivery and Inhalation Devices Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GF447EBBE122EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF447EBBE122EN.html>